Galapagos Stock (NASDAQ:GLPG), Trade Ideas

Galapagos

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

New,York,,Usa,-,18,March,2021:,Galapagos,Company,Logo

Analyst Color

Biotech

News

Downgrades

Health Care

General

GILD

GLPG

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets.

Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst

Contracts

On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG).

European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

BIGC

CVNA

DISH

NKTR

NTES

OCEA

OPEN

WISH

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Galapagos NV - American Depositary Shares

Galapagos NV

Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) reported quarterly earnings of $5.06 per share which beat the analyst consensus estimate of $3.55 by 42.54 percent. The company reported quarterly sales of $1.468 billion which beat the analyst consensus estimate of $1.288 billion by 14.01 percent. This is a 14.78 percent increase over sales of $1.279 billion the same period last year.

Earnings

Earnings Beats

Meritage Homes Q1 2024 GAAP EPS $5.06 Beats $3.55 Estimate, Sales $1.468B Beat $1.288B Estimate

Alerus Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) reported quarterly earnings of $0.32 per share which met the analyst consensus estimate. This is a 20 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $47.542 million which beat the analyst consensus estimate of $47.448 million by 0.20 percent. This is a 2.80 percent decrease over sales of $48.911 million the same period last year.

ALRS

Alerus Finl Q1 2024 GAAP EPS $0.32, Inline, Sales $47.542M Beat $47.448M Estimate

Guidance

PLXS

Plexus Sees Q3 Revenue Of $960M-$1.00B (Est $1.022B), Adj EPS Of $1.22-$1.37 (Est $1.09)

SLM Sees FY24 EPS $2.60-$2.70 Vs $2.69 Est

SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.07 by 18.69 percent. This is a 170.21 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $387.00 million which missed the analyst consensus estimate of $387.89 million by 0.23 percent. This is a 4.46 percent decrease over sales of $405.07 million the same period last year.

Earnings Misses

SLM Q1 Adj $1.27 Beats $1.07 Estimate, Sales $387.00M Miss $387.89M Estimate

Wyndham Hotels & Resorts Raises FY24 Adjusted EPS Outlook From $4.11-$4.23 To $4.18-$4.30, Est $4.21

Horizon Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBNC#NASDAQ">HBNC</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.31 by 3.23 percent. This is a 25.58 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $53.217 million which missed the analyst consensus estimate of $54.377 million by 2.13 percent. This is a 2.99 percent decrease over sales of $54.857 million the same period last year.

HBNC

Horizon Bancorp Q1 2024 Adj EPS $0.32 Beats $0.31 Estimate, Sales $53.217M Miss $54.377M Estimate

WIIM

VIST

Vista Energy shares are trading lower after the company reported worse-than-expected Q1 financial results.

2024 Guidance
The Company has increased the low end of its previously issued fully diluted 2024 AFFO per share estimate and now expects that 2024 AFFO per share on a fully diluted basis will be within a range of $1.72 to $1.75.
Note: The Company does not provide guidance for the most comparable GAAP financial measure, net income, or a reconciliation of the forward-looking non-GAAP financial measure of AFFO to net income computed in accordance with GAAP, because it is unable to reasonably predict, without unreasonable efforts, certain items that would be contained in the GAAP measure, including items that are not indicative of the Company's ongoing operations, such as, without limitation, potential impairments of real estate assets, net gain/loss on dispositions of real estate assets, changes in allowance for credit losses and stock-based compensation expense. These items are uncertain, depend on various factors, and could have a material impact on the Company's GAAP results for the guidance period.

EPRT

Essential Properties Realty Trust Updates 2024 AFFO Guidance To $1.72-$1.75 per Share

BMRN

BioMarin Pharmaceutical shares are trading lower after the company reported Q1 financial results.

O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) reported quarterly earnings of $9.27 per share which beat the analyst consensus estimate of $9.26 by 0.11 percent. The company reported quarterly sales of $3.98 billion which met the analyst consensus estimate. This is a 7.34 percent increase over sales of $3.71 billion the same period last year.

ORLY

O'Reilly Automotive Q1 2024 Adj EPS $9.27 Beats $9.26 Estimate, Sales $3.98B Inline

QuantumScape (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is unchanged from the same period last year.

QuantumScape Q1 2024 GAAP EPS $(0.24), Inline

GSHD

Goosehead Insurance Sees FY24 Revenue $290M-$310M Vs $312.208M Est.

Guidance for 2024
Management reiterates its estimated full-year 2024 earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items, guidance range of $23.30 to $23.70. Management anticipates providing updated 2024 earnings guidance and related subsidiary operating metrics as part of the June 30, 2024 earnings press release.

Chemed Sees FY24 EPS $23.30-$23.70 Vs $23.52 Est.

PEGA

Pegasystems Says In Great Position To Accelerate Profitable Growth, Given Its Financial Strength And Differentiated GenAI Capabilities

Second Quarter 2024 Financial Outlook
Impinj provides guidance based on current market conditions and expectations; actual results may differ materially. Please refer to the comments below regarding forward-looking statements. The following table presents Impinj's financial outlook for the second quarter of 2024 (in millions, except per share data):
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Three Months Ending</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">June 30, 2024(1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$96.0 to $99.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP Net income</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$5.9 to $7.4&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA income</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$23.9 to $25.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP Weighted-average shares — diluted</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">29.0 to 29.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP Net income per share — diluted</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.20 to $0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Net income</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$21.7 to $23.2</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Weighted-average shares — diluted(2)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">31.7 to 31.9</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Net income per share — diluted(2)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.72 to $0.77</td>
</tr>
</tbody>
</table>
</figure>
(1) The outlook for our revenue and related results for the second quarter ended June 30, 2024 includes $15 million related to recognition of an annual license fee for use of our intellectual property. (2) Non-GAAP diluted net income per share includes the impact of our convertible debt using the if-converted method, which assumes full share settlement. Interest expense is added back to net income and weighted average shares includes total shares issuable at conversion of 2.6 million.
A reconciliation between GAAP and non-GAAP financial measures is provided in the "Non-GAAP Financial Measures" section below.

Impinj Sees Q2 GAAP EPS $0.20-$0.25 Vs $0.19 Est.; Non-GAAP EPS $0.72-$0.77; Revenue $96M-$99M Vs $78.93M Est.

Management

Jefferies CEO Rich Handler Sells 1.5M Shares Of Stock; Co. Says Sale Was Made To Facilitate The Purchase Of A Personal Boat And To Pay Tax Obligations

Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.60 by 21.67 percent. This is a 6.41 percent decrease over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $90.578 million which beat the analyst consensus estimate of $89.437 million by 1.28 percent. This is a 3.16 percent decrease over sales of $93.531 million the same period last year.

Origin Bancorp Q1 2024 Adj EPS $0.73 Beats $0.60 Estimate, Sales $90.578M Beat $89.437M Estimate

The debate over U.S. <a href="https://www.benzinga.com/cannabis">cannabis </a>legalization is complex, spanning economics, law and social justice. As of April 2024, recreational cannabis is legal in 24 states, and half of all Americans live in a state where recreational cannabis consumption is permitted. Despite this, cannabis remains illegal under federal law, a status investors believe may soon change. But the path to change is still forming. 
<h3 class="wp-block-heading">Unpacking the Complex Journey Towards National Legalization</h3>
How this change will occur is yet to be discovered. In a recent <a href="https://twitter.com/YahooFinance/status/1781419284708680045">interview</a>, industry expert and manager at <a href="https://www.benzinga.com/markets/cannabis/24/04/38098944/poseidon-investment-fund-ventures-into-ny-market-via-start-up-pca">Poseidon </a>Investment Fund <a href="https://www.benzinga.com/markets/cannabis/24/02/37132673/the-queen-of-marijuana-investing-used-psychology-to-launch-her-successful-cannabis-investment-fu">Emily Paxhia</a>, laid out three main pathways along which cannabis legalization might happen. 
Let&#8217;s break them down.
<h3 class="wp-block-heading">Federal Rescheduling Route</h3>
The initiative to <a href="https://www.benzinga.com/markets/cannabis/24/04/38032920/deas-resistance-to-cannabis-rescheduling-ignites-policy-clash">reclassify cannabis</a> under federal law is spearheaded by a push to designate it as a Schedule III substance, signaling recognized medical benefits and lower abuse potential.&nbsp;
This effort is under review by the DEA, following a recommendation from the HHS. The political will for this change is robust, bolstered by favorable public opinion across both ailes.&nbsp;
However, the DEA&#8217;s process is meticulous, somewhat unpredictable and also lacks a definitive timeline for their final announcements.
<h3 class="wp-block-heading">The Legislative Route</h3>
Optimism is high for legislative progress in 2024, particularly following the advancement of the <a href="https://www.benzinga.com/topic/safer-banking-act">SAFER Banking Act</a> through the Senate Banking Committee. This legislation aims to bridge the gap between federal and state laws by facilitating banking and financial services for cannabis businesses. By reducing financial risks and increasing transparency, the SAFER seeks to foster industry growth and stability.
The cons are that it stops short of altering cannabis&#8217; federal legal status and the road to approval implies a long and sinuous legislative effort.
<h3 class="wp-block-heading">The Judicial Route</h3>
This pathway opened up as a group of cannabis companies in Massachusetts decided to defy the interpretation of the Controlled Substances Act in court. 
Success in this case could not only lead to <a href="https://www.benzinga.com/markets/cannabis/24/04/38281470/the-court-case-that-could-change-the-cannabis-industry-forever-and-how-it-affects-rescheduling">more equitable tax treatment for cannabis businesses </a>but might also prompt a retrospective financial adjustment, benefiting companies that have previously <a href="https://www.benzinga.com/markets/cannabis/24/04/38387994/california-cannabis-industry-is-drowning-in-debt-732m-owed-in-taxes-72-by-companies-already-clos">faced harsh fiscal conditions.</a>
<h3 class="wp-block-heading">What To Expect In The Near Future</h3>
As the multi-billion dollar cannabis industry continues to expand and consolidate, pressure mounts for federal legalization. If cannabis receives the federal green light, restrictions on lending and banking for the industry are relaxed, or the Massachusetts lawsuit favors the plaintiffs then the industry is poised to access more capital. This will boost consolidation while enhancing production efficiency, and scale operations significantly. 
As these three paths unfold, the future of cannabis legalization remains a central issue, with implications that reach far beyond the confines of the industry.&nbsp;

Cannabis

Politics

Three Pathways To Federal Cannabis Legalization That Investors Are Watching Closely

KALU

Kaiser Aluminum Sees FY24 Conversion Revenue To Improve 2%-3%

The biotech industry is thriving on growing applications across sectors from healthcare to agriculture, favorable government funding and policies, and technological breakthroughs. Amid this backdrop, quality biotech stocks UroGen Pharma (URGN), Foghorn Therapeutics (FHTX), and Galapagos (GLPG) might be ideal additions to one's watchlist. Read on… The biotech market is rapidly expanding, transforming industries such as healthcare, agriculture, and industrial processing through innovative technologies and approaches. Therefore, investors could consider investing in top biotech stocks UroGen Pharma Ltd. (<a href="https://stocknews.com/stock/URGN/">URGN</a>), Foghorn Therapeutics Inc. (<a href="https://stocknews.com/stock/FHTX/">FHTX</a>), and Galapagos NV (<a href="https://stocknews.com/stock/GLPG/">GLPG</a>).
This year, the biotech and healthcare sectors are <a href="https://www.forbes.com/sites/forbesagencycouncil/2024/02/08/6-predictions-for-healthcare-and-biotech-in-2024/?sh=73039f15741c">expected to focus on efficiency and conservative strategies</a>, expecting fewer but higher-value acquisitions. Also, the surge in telehealth, growing AI adoption, and rising demand for brain health diagnostics and treatment are set for a revolution in the biotech industry driven by increased demand and innovation.
Besides, the biopharma industry started 2024 with guarded optimism, buoyed by market rebounds and increased merger activity, alongside prospects for new drug approvals and innovative treatments.
In addition, the rising prevalence of chronic diseases and regulatory approvals will drive growth in the biopharmaceutical market, supported by investments in clinical trials and the presence of contract organizations. The global biopharma market is poised to grow at a <a href="https://www.precedenceresearch.com/biopharmaceutical-market#:~:text=The%20global%20biopharmaceuticals%20market%20was,14.8%25%20from%202023%20to%202032.">CAGR of 14.8%</a> to reach $1.42 trillion by 2032.
Moreover, the US bioeconomy, <a href="https://www.greenbiz.com/article/us-bioeconomy-worth-950-billion-and-growing-thanks-these-federal-policies">valued at more than $950 billion</a>, is well-placed for significant growth due to federal policies focusing on development and commercialization, including the Inflation Reduction Act and Biden's Bioeconomy Executive Order, which aim to accelerate bioenergy technologies and streamline regulatory pathways.
Rapid technological advancements, particularly in areas like genomics, proteomics, and bioinformatics, have led to significant breakthroughs in drug discovery, development, and manufacturing. Recent innovations in biotech are moving toward trends like AI, machine learning, data analytics, and automation to optimize production.
The <a href="https://www.precedenceresearch.com/artificial-intelligence-in-biopharmaceutical-market">global AI in the biopharmaceutical market</a> is projected to total about $14.07 billion by 2032, exhibiting a CAGR of 32.3%.
Considering these conducive trends, let's discuss the fundamentals of three <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, beginning with the third choice.
Stock #3: UroGen Pharma Ltd. (<a href="https://stocknews.com/stock/URGN/">URGN</a>)
URGN is a biotechnology company that develops and commercializes novel solutions for specialty cancers and urothelial diseases. The company provides RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to enhance the therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
On January 24, 2024, URGN submitted the Chemistry, Manufacturing, and Controls (CMC) section of the New Drug Application (NDA) for UGN-102 (mitomycin) for the intravesical solution to the US FDA. The submission marks a major milestone for URGN, underscoring its dedication to advancing innovative therapies for individuals grappling with muscle-invasive bladder cancer.
URGN's trailing-12-month <a href="https://www.investopedia.com/terms/g/gross_profit_margin.asp">gross profit margin</a> of 87.92% is 53.5% higher than the industry average of 57.27%. Likewise, the stock's trailing-12-month cash per share of 3.87 is 199.5% higher than the industry average of 1.29.
During the third quarter, which ended September 30, 2023, URGN's revenue and gross profit grew 29.5% and 31.3% year-over-year to $20.85 million and $18.49 million, respectively. The company's total operating expenses dropped marginally year-over-year to $31.99 million.
As of September 30, 2023, the company's total assets amounted to $193.63 million, compared to its total assets of $135.62 million as of December 31, 2022.
Street expects URGN's revenue to grow 33% year-over-year to $108.70 million for the fiscal year ending December 2024. Its EPS for the same period is estimated to improve 26.3% year-over-year. Moreover, the company surpassed consensus revenue estimates in three of the trailing four quarters.
URGN's shares have gained 42.8% over the past three months and 83.9% over the past nine months to close the last trading session at $18.33. Also, it surged marginally intraday.
URGN's <a href="https://stocknews.com/powr-ratings/">POWR</a><a href="https://stocknews.com/powr-ratings/"> Ratings</a> reflect this promising outlook. The stock has an overall B rating, translating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
URGN has a B grade for Growth. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #34 among 360 stocks.
In addition to the POWR Ratings stated above, one can access URGN's additional Value, Momentum, Stability, Sentiment, and Quality ratings <a href="https://stocknews.com/stock/URGN/">here</a>.
Stock #2: Foghorn Therapeutics Inc. (<a href="https://stocknews.com/stock/FHTX/">FHTX</a>)
FHTX is a clinical-stage biopharmaceutical company focused on developing medicines targeting genetic dependencies within the chromatin regulatory system. Through its proprietary Gene Traffic Control platform, the company aims to advance treatments for cancers such as metastatic uveal melanoma and acute myeloid leukemia.
On February 8, 2024, FHTX announced that Lilly had selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. Lilly aims to file an IND for FHD-909 in the second quarter of fiscal 2024. The main target patient population is BRG1 mutated non-small cell lung cancer (NSCLC).
Also, in December 2021, FHTX entered a collaboration with Lilly to develop novel oncology medicines. The partnership comprises a US 50/50 co-development and co-commercialization deal for Foghorn's Selective BRM oncology program and an additional undisclosed oncology target.
The collaboration also includes three discovery programs using Foghorn's proprietary Gene Traffic Control platform.
FHTX's trailing-12-month CAPEX/Sales of 4.47% is 10.7% higher than the industry average of 4.04%. Also, its trailing-12-month cash per share of 1.67 is 29% higher than the industry average of 1.29%.
For the third quarter, which ended September 30, 2023, FHTX's collaboration revenue and net income increased 163.5% and 39.5% from a year-ago quarter to $17.48 million and $3.47 million, respectively. The company's total operating expenses declined 1% year-over-year to $34.56 million.
In addition, as of September 30, 2023, the company's total liabilities were reduced to $370.81 million, compared to its total liabilities of $404.77 million as of December 31, 2022.
Analysts expect FHTX's revenue to grow 25.1% year-over-year to $40.59 million for the fiscal year ending December 2024. The company's EPS for the ongoing year is projected to grow 7.8% year-over-year.
The stock has gained 106.1% over the past month to close the last trading session at $7.73.
FHTX's sound fundamentals are reflected in its POWR Ratings. The stock has an overall A rating, translating to a Strong Buy in our proprietary rating system.
The stock has a B grade for Sentiment and Quality. In the same industry, FHTX is ranked #33.
To access additional ratings for FHTX's Growth, Value, Momentum, and Stability, <a href="https://stocknews.com/stock/FHTX/">click here</a>.
Stock #1: Galapagos NV (<a href="https://stocknews.com/stock/GLPG/">GLPG</a>)
Headquartered in Mechelen, Belgium, GLPG is a biopharmaceutical company dedicated to developing innovative medicines addressing significant medical needs. Its pipeline includes filgotinib for various conditions and advanced-stage CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia.
On January 4, 2024, GLPG entered a strategic partnership agreement with Thermo Fisher Scientific, Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>) for the decentralized manufacturing of Galapagos' point-of-care CAR-T product candidate in the San Francisco area. This deal follows a previously announced collaboration with Landmark Bio for decentralized CAR-T manufacturing in the Boston area.
Dr. Paul Stoffels, CEO and Chairman of GLPG, said, "Together we will establish a decentralized CAR-T manufacturing network in the San Francisco area to support the rollout of our pivotal clinical trials and enhance our market readiness. This collaboration will advance Galapagos' commitment to better meeting patient needs and making CAR-T therapies available to more patients through the rapid delivery of fit CAR-T cells."
GLPG's trailing-12-month CAPEX/Sales of 7.45% is 84.6% higher than the industry average of 4.04%. Its trailing-12-month cash per share of 2.65 is 105.7% higher than the industry average of 1.29.
GLPG reported total net revenues of €239.72 million ($259.53 million) in the fiscal year ended December 31, 2023. The company's net profit and income per share amounted to €211.70 million ($229.19 million) and €3.21, compared to the prior year's net loss and loss per share of €217.99 million ($236 million) and €3.32, respectively.
As of December 31, 2023, the company's total liabilities amounted to €1.56 billion ($1.69 billion), compared to €2.21 billion ($2.39 billion) as of December 31, 2022.
Street expects GLPG to report revenue of $439.74 million for the fiscal year ending December 2024. In addition, the company surpassed consensus revenue estimates in each of the trailing four quarters, which is promising.
The stock has declined 2.7% intraday to close the last trading session at $35.11.
GLPG's POWR Ratings reflect its promising prospects. The stock has an overall B rating, translating to a Buy in our proprietary rating system.
The stock has a B grade for Growth, Value, and Sentiment. Within the same industry, GLPG is ranked #25.
<a href="https://stocknews.com/stock/GLPG/">Click here</a> to see GLPG's ratings for Momentum, Stability, and Quality.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
GLPG shares rose $0.11 (+0.31%) in premarket trading Friday. Year-to-date, GLPG has declined -13.63%, versus a 6.89% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/glpg-urgn-fhtx-tmo-3-biotech-stocks-climbing-the-ranks-to-watch/>3 Biotech Stocks Climbing the Ranks to Watch</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Climbing the Ranks to Watch

Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more

Galapagos NV - ADR (GLPG) is down -2.61%% today. GLPG has an Overall Score of 33. Find out what this means to you and get the rest of the rankings on GLPG!See Full GLPG ReportGLPG stock closed at $32.95 and is down -$0.86 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as m

Galapagos NV - ADR (GLPG) Down 2.61% in Premarket Trading

BofA downgrades Galapagos to Underperform over lack of catalysts in the near term

Galapagos NV (GLPG) has released an update. Galapagos NV has strengthened its board by appointing Andrew Dickinson, the Chief Financial Officer of ...

Galapagos NV Welcomes New Board Member

Galapagos NV (GLPG) has released an update. Galapagos NV has released its 2023 annual report and scheduled its Annual and Extraordinary Shareholder...

Galapagos NV Announces Shareholders' Meetings and 2023 Report

Galapagos NV (GLPG) has released an update. Galapagos NV is presenting promising preliminary data from their Phase 1/2 studies on innovative CAR-T ...

Galapagos NV Unveils CAR-T Therapy Advances

AGRX

AMPE

APTO

AQMS

AREC

ASTS

ATNM

AULT

AXDX

AYRO

BLRX

BZFD

CMCL

CTAS

CWCO

DARE

DCTH

DLNG

DNMR

DOMH

DOYU

DTIL

ERNA

ESLT

FHTX

GREE

HEPS

IDEX

ITRM

LGMK

LITB

MAXN

MDAI

NCNO

NVVE

OGEN

ORGS

OUST

PAYS

PAYX

PLBY

REKR

RKDA

SMTC

STIX

TIVC

URGN

VIOT

VRNT

VSTM

VUZI

WPRT

XELA

XXII

Press Releases

BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Galapagos presents at EBMT-EHA annual meeting 2024

Financing

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

Galapagos announces full year 2023 results and outlook for 2024

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024